Clinical Trial: A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Oxybutynin Chloride Extended-Release Tablets to Improve Early Continence Recovery After Robotic Prostatectomy

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06966778) titled 'A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Oxybutynin Chloride Extended-Release Tablets to Improve Early Continence Recovery After Robotic Prostatectomy' on May 04.

Brief Summary: The goal of this double-blind, randomized, placebo-controlled study is to evaluate whether oxybutynin chloride extended-release tablets can improve early continence recovery after robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.

The main questions it aims to answer are:

[Does oxybutynin chloride improve continence recovery after RARP compared to a placebo?] [What are the predicto...